Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7. doi: 10.6004/jnccn.2012.0114.


The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

Publication types

  • Practice Guideline

MeSH terms

  • Abiraterone Acetate
  • Androgen Antagonists / therapeutic use
  • Androstadienes / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Brachytherapy
  • Docetaxel
  • Humans
  • Male
  • Orchiectomy
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / radiotherapy
  • Prostatic Neoplasms / therapy*
  • Taxoids / therapeutic use
  • Tissue Extracts / therapeutic use


  • Androgen Antagonists
  • Androstadienes
  • Antineoplastic Agents
  • Taxoids
  • Tissue Extracts
  • Docetaxel
  • sipuleucel-T
  • Abiraterone Acetate